185 related articles for article (PubMed ID: 20062915)
1. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
Jiang J; Hu Y; Zhang J; Yang J; Mueck W; Kubitza D; Bauer RJ; Meng L; Hu P
Thromb Haemost; 2010 Jan; 103(1):234-41. PubMed ID: 20062915
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Kubitza D; Becka M; Roth A; Mueck W
Curr Med Res Opin; 2008 Oct; 24(10):2757-65. PubMed ID: 18715524
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.
Zhao X; Sun P; Zhou Y; Liu Y; Zhang H; Mueck W; Kubitza D; Bauer RJ; Zhang H; Cui Y
Br J Clin Pharmacol; 2009 Jul; 68(1):77-88. PubMed ID: 19660005
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
[TBL] [Abstract][Full Text] [Related]
5. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.
Mueck W; Becka M; Kubitza D; Voith B; Zuehlsdorf M
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):335-44. PubMed ID: 17595891
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
[TBL] [Abstract][Full Text] [Related]
9. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz R
Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
[TBL] [Abstract][Full Text] [Related]
14. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban: a novel anticoagulant.
Ali M; Nawal CL
Indian J Med Sci; 2010 Nov; 64(11):520-8. PubMed ID: 23051944
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
19. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]